MedTrace Logo

Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer

NCT02938195 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-10-19

No results posted yet for this study

Summary

The investigators designed a new preoperative chemoradiotherapy regimen to focus on the most important radiation area and hope to reduce the radiation volume and try to reduce the postoperative mortality and treatment-related mortality.

Conditions

  • Esophageal Cancer
  • Chemoradiation
  • Surgery

Interventions

RADIATION

radiotherapy

The clinical target volume of radiotherapy only includes the visible tumor and lymph nodes and the investigators wouldn't do any prophylactic radiation treatment.

PROCEDURE

Surgery

Surgery would be done 4-8 weeks after neoadjuvant chemoradiotherapy.

Sponsors & Collaborators

  • Shanghai Chest Hospital

    lead OTHER

Principal Investigators

  • Xiaolong Fu, Ph.D · Department of Radiation Oncology,Shanghai Chest Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02938195 on ClinicalTrials.gov